Study: Early Identification Needed for Mesothelioma Advances

Professor John Cherrie at Heriot-Watt University in the United Kingdom believes future treatment advances and improved patient outcomes for mesothelioma rests with a formula to better identify and screen high-risk patients. It could make an early diagnosis of the asbestos-related cancer much more common. Cherrie said the current standard — which typically results in a late-stage diagnosis and a poor prognosis — prevents novel treatment studies and the development of any pre-emergent strategy to combat the aggressive cancer. “We don’t pretend to have a medical cure that will help immediately, but until we can start identifying patients earlier, we can’t even try out what might work,” Cherrie, an occupational medicine specialist in the School of Engineering and Physical Sciences at Heriot-Watt, told Asbestos.com. “The patients are usually too sick. It’s tough to make progress that way.” Cherrie is the lead author in a study published recently in the International Journal of Hygiene and Environmental Health, detailing the asbestos-exposure formula he believes would work. “Right now, we don’t have a way of identifying early-stage disease,” he said. “Usually by the time it is diagnosed, it’s virtually untreatable. We want to find a way to change that.” Pre-Emergent Treatment Strategies Mesothelioma is caused almost exclusively by exposure to toxic asbestos, typically in long-term occupationa...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Activity emission potential biomarkers for mesothelioma chemoprophylaxis strategies early diagnosis mesothelioma Early identification of mesothelioma early screening asbestos Heriot-Watt University high-risk mesothelioma indwelling pleural Source Type: news

Related Links:

Radiation oncologist Dr. Andrea McKee believes deaths from lung cancer — including those related to asbestos exposure — could be reduced significantly by increased utilization of early CT screening. McKee, chair of radiation oncology at Lahey Hospital and Medical Center in Burlington, Maine, has been a strong proponent of early screening for several years. “We could be saving tens of thousands of lives every year with this,” McKee told The Mesothelioma Center at Asbestos.com. “There is nothing else like it. The life-saving potential is the most important thing that has happened to cancer in my...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
We aimed to evaluate the diagnostic utility of PET-CT in differential diagnosis of MPE.Patients with pleural effusion and cancer who underwent PE T-CT were studied. Thoracentesis was performed for all cases.Sudy population consisted of 69 patients with a mean age of 63.55. Definitive diagnosis of MPE was confirmed by cytopathology In 16 cases, effusion was paramalignant. Malignant cells were detected in fluids with no FDG uptake in 13 lung cancer, 3 mesothelioma, 2 breast cancer, 2 colon cancer, 1 ovarian cancer, 1 gastric cancerand 1 endometrium cancer cases. The sensitivity of PET-CT in malignant pleural effusion is foun...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pleural and Mediastinal Malignancies Source Type: research
A team of French researchers led by Dr. Christophe Blanquart has identified a substance that may better define the severity of malignant pleural mesothelioma (MPM) in the body and provide clues to more effectively manage the rare cancer. Brain-derived neurotrophic factor, as the name indicates, is a protein found in the brain. BDNF is a growth factor and also appears in other tissues in the body. “It seems that BDNF could be a prognostic marker for MPM patients,” Blanquart told The Mesothelioma Center at Asbestos.com. “The level of BDNF in pleural fluids could reflect the severity of disease.” The...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsReduction of postoperative complications after CRS –HIPEC is essential for optimal short- and long-term outcomes. For assessing total burden of postoperative complications per patient, CCI is superior to CDC and more sensitive for assessing surgery- and cancer-related outcomes after CRS–HIPEC.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Physicians may soon use artificial intelligence (AI) and medical images to study tumors without a biopsy. The techniques developed to study tumors in this new way are described in the September 1 issue of The Lancet Oncology. Along with helping physicians learn more about tumors without surgery, the new approach should help identify which cancer patients will respond best to cutting-edge immunotherapy treatments. The AI techniques could be useful for “predicting clinical outcomes of patients treated with immunotherapy when validated by further prospective randomized trials,” the authors wrote. Immunotherapy tre...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
John Feal believes more people will die from illnesses related to 9/11 than from the terrorist attack at the World Trade Center. He should know. He’s a first responder who witnesses it every day. And he is not alone in his belief. Feal, a longtime advocate for Sept. 11 survivors and those dying from diseases related to the terrorist attacks, will again host the annual naming ceremony at the 9/11 Responders Remembered Park in Smithtown, Long Island. Each year he reads the names of those who have died within the past year. And each year, the list is longer than the last. On the 17th anniversary of the terrorist attack...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
AbstractPurposeFew large-scale studies have investigated sex differences in cancer survival and little is known about their temporal and age-related patterns.MethodsWe used cancer registry data for first primary cancers diagnosed between 1982 and 2015 in Victoria, Australia. Cases were followed until the end of 2015 through linkage to death registries. Differences in survival were assessed for 25 cancers using the Pohar-Perme estimator of net survival and the excess mortality rate ratio (EMRR) adjusting for age and year of diagnosis.ResultsFive-year net survival for all cancers combined was lower for men (47.1%; 95% CI 46....
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
DiscussionThe qualitative and quantitative data gathered in this feasibility trial will hopefully pave the way to designing a robust full phase III trial to investigate the potential synergistic effect of ZA and current standard treatment for MPM, cisplatin-pemetrexed combination chemotherapy.Trial registrationISRCTN Registry,ISRCTN45536692. Registered on 9 August 2016. EudraCT no. 2015 –004433-26.
Source: Trials - Category: Research Source Type: clinical trials
Cancer patients — including those with mesothelioma — who receive complementary therapy are likely to die sooner than those who use only conventional treatment, according to researchers at Yale School of Medicine. Patients receiving complementary medicine also were more inclined to forego at least one component of their conventional treatment regimen. The study was done by a team from the Yale Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine. JAMA Oncology published the study July 19. “The study was about patients who were using unproven therapies for treatment...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsThis survey is the first LA effort to publish current practice indications and treatment protocols of PD. Achieving consensus of best therapeutic options is essential to provide the best possible outcomes for patients with PD who could benefit from CRS with HIPEC therefore aiming at standardization of the procedure.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | CT Scan | Environmental Health | Epidemiology | Immunotherapy | Mesothelioma | Occupational Health | Respiratory Medicine | Study | Toxicology | UK Health | X-Ray